Clinical Trial

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-08-26; most recent amendment 2026-02-04.
Trial Details
NCT Number NCT06574568
Lead Sponsor Excyte Biopharma Ltd
Conditions Relapsed or Refractory Multiple Myeloma
Enrollment 70 participants
Start Date 2024-06-14
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-05